Cephalon named J. Kevin Buchi CEO and a member of the company’s board of directors. Buchi, who was previously COO and CFO at the company and has led business development for the past seven years, replaces founder Frank Baldino in that role. Baldino died last week at age 57. Cephalon said the board will address the role of chairman in the future, and William Egan will continue to serve as the company’s independent presiding director.
PhRMA named four new members to its board of directors, including: Ian Read, Pfizer’s president and CEO; Jerzy Gruhn, president of Novo Nordisk in the US; Mark Iwicki, president and COO of Sunovion Pharmaceuticals, and Staffan Schuberg, president of Lundbeck’s US unit.
